Filing Details
- Accession Number:
- 0000899243-20-025361
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2020-09-16 18:11:34
- Reporting Period:
- 2020-09-14
- Accepted Time:
- 2020-09-16 18:11:34
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 1701541 | Black Diamond Therapeutics Inc. | BDTX | () | 4 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1637054 | Brent Hatzis-Schoch | C/O Black Diamond Therapeutics, Inc. 139 Main Street Cambridge MA 02142 | See Remarks | No | Yes | No | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock | Acquisiton | 2020-09-14 | 4,078 | $3.20 | 7,078 | No | 4 | M | Direct | |
| Common Stock | Disposition | 2020-09-14 | 2,685 | $30.76 | 4,393 | No | 4 | S | Direct | |
| Common Stock | Disposition | 2020-09-14 | 1,186 | $31.42 | 3,207 | No | 4 | S | Direct | |
| Common Stock | Disposition | 2020-09-14 | 207 | $32.55 | 3,000 | No | 4 | S | Direct |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | M | Direct | |
| No | 4 | S | Direct | |
| No | 4 | S | Direct | |
| No | 4 | S | Direct |
Reported Derivative Transactions
| Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
|---|---|---|---|---|---|---|---|
| Common Stock | Stock Option (Right to Buy) | Disposition | 2020-09-14 | 4,078 | $0.00 | 4,078 | $3.20 |
| Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
|---|---|---|---|---|---|---|
| 198,498 | 2029-06-11 | No | 4 | M | Direct |
Footnotes
- Shares sold pursuant to a pre-established 10b5-1 trading plan effective as of June 12, 2020
- The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $30.20 to $31.145, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
- The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $31.21 to $31.975, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
- The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $32.28 to $32.70, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
- 25% of the shares subject to this option vested and became exercisable on May 22, 2020, with the remainder vesting in 36 equal monthly installments thereafter.
Billionaire Hedge Funds
